Saturday, February, 23, 2019 01:58:08

Contribution By Shikha Sinha


India and the UK ink MoU to conjointly work on cancer research

The Ministry of Science and Technology has recently announced that India and the United Kingdom have both signed a Memorandum of Understanding (MoU) for collaborating on cancer research at the Inaugural Researchers’ Conference in New Delhi. The India-UK Cancer Research Initiative focused on developing affordable …

IMV joins Merck to gauge DPX-Survivac, declares Phase 2 basket trial

IMV Incorporation, a clinical stage biopharmaceutical company, has reportedly declared the expansion of its clinical program through a Phase 2 basket trial assessing its prime drug, DPX-Survivac, combined with KEYTRUDA (pembrolizumab) and cyclophosphamide, in patients suffering from recurrent or advanced solid tumors. Frederic Ors, Chief …

Pfizer’s inhibitor drug given Breakthrough Therapy designation by FDA

Pfizer recently made an announcement confirming that its experimental oral inhibitor, Janus kinase 3 (JAK3) or PF-06651600, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Apparently, the inhibitor is being developed for treating patients suffering from alopecia areata, …

CHAOS approach taps CRISPR to alter multiple genes in bacterial cells

Researchers at the University of Colorado Boulder have reportedly developed an unconventional genetic disruption strategy that successfully stymies the growth of antibiotic-resistant bacteria, giving scientists an edge over deadly superbugs. According to data from the Centers for Disease Control, these multiple drug resistant pathogens — …

Pfizer brings the development of DMD candidate Domagrozuma to a halt

Renowned New York-based pharma magnate Pfizer Inc., has reportedly axed two trials of its Domagrozuma antibody. As per sources, the candidate development has been halted on the grounds of its disappointing failure to meet the required efficacy targets. For the uninitiated, the anti-myostatin antibody is …